Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953626 | 0.85 | HRH3 (0.43) | HRH3ALDH1A1SMN1; SMN2NCF1 | |
| SCHEMBL3586642 | 0.83 | HRH3 (0.47) | HRH3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2972644 | 0.80 | MC4R (0.46) | ALDH1A1MEN1KMT2ASMN1; SMN2NCF1 | |
| SCHEMBL60705 | 0.69 | HRH3 (0.66) | HRH3ALDH1A1CYP2C9ALOX15HSD17B10 | |
| SCHEMBL15467001 | 0.69 | HRH3 (0.87) | HRH3ALDH1A1CYP2C9ALOX15HSD17B10 | |
| SCHEMBL17157069 | 0.68 | SMN1; SMN2 (0.55) | HRH3ALDH1A1CYP2C9MEN1KMT2A | |
| SCHEMBL7568331 | 0.68 | HRH3 (0.63) | HRH3ALDH1A1CYP2C9ALOX15HSD17B10 | |
| SCHEMBL8263606 | 0.67 | ALDH1A1 (0.63) | HRH3ALDH1A1CYP2C9ALOX15HSD17B10 | |
| SCHEMBL4143256 | 0.67 | HTT (0.61) | HRH3ALDH1A1CYP2C9ALOX15HSD17B10 | |
| SCHEMBL1472855 | 0.67 | GFER (0.64) | HRH3ALDH1A1CYP2C9ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253737-B3 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-11453666-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-27 | — | — | US | claimed |
| CN-107428752-B | Home chemokine inhibiting compounds | 癌症研究科技有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-20200283435-A1 | Autotaxin Inhibitory Compunds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-09-10 | — | — | US | claimed |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | claimed |
| WO-2016124939-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | claimed |
| WO-2006070202-A1 | PYRAZOLE DERIVATIVES HAVING KINASE MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | claimed |
| EP-3253737-B3 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11453666-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
| CN-107428752-B | Home chemokine inhibiting compounds | 癌症研究科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20200283435-A1 | Autotaxin Inhibitory Compunds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10654846-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006070202-A1 | PYRAZOLE DERIVATIVES HAVING KINASE MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| EP-1651612-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | Astex Therapeutics Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | HRH3 3763/4885ALDH1A1 1318/4885CYP2C9 4247/4885 |
| US-10654846-B2 | Autotaxin inhibitory compounds | ENPP2, RNASE1, ATXN10 | HRH3 982/4885ALDH1A1 2181/4885CYP2C9 4627/4885 |
| US-20200283435-A1 | Autotaxin Inhibitory Compunds | ENPP2, RNASE1, ATXN10 | HRH3 1377/4885ALDH1A1 2473/4885CYP2C9 4564/4885 |
| US-11453666-B2 | Autotaxin inhibitory compounds | ENPP2, RNASE1, ATXN10 | HRH3 1100/4885ALDH1A1 2014/4885CYP2C9 4568/4885 |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | ENPP2, RNASE1, ATXN10 | HRH3 982/4885ALDH1A1 2181/4885CYP2C9 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.